CD38 and plasma cell myeloma: This in line with the results of our previous studies showing that human CD38-specific nanobody-based hcAbs potently induced ADCC of several human lymphoma and myeloma cell lines, including LP-1 myeloma, CA-46 and Daudi Burkitt lymphoma (35, 51).